Post Profile






Clinical Trial Of Malaria Vaccine Begins In Africa

The vaccine, RTS,S, developed by GlaxoSmithKline (GSK) Biologicals and PATH Malaria Vaccine Initiative (MVI), is currently in phase III clinical trials and has previously reduced episodes of malaria in infants and young children by more than 50%. The Liverpool team, in collaboration with the University College of Medicine, Malawi, are working in Blantyre over the next three years to investigate how to maximise its effectiveness when delivered through the childhood immunisation programme.
read more

share

Related Posts


Malaria Vaccine Candidate, RTS,S Reduces The Risk Of Malaria By Half In African Children Aged 5 To 17 Months

Health : Medical News Today

First results from a large-scale Phase III trial of RTS,S, published online in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clin...

Malaria vaccine protects children for up to 18 months

Health : Medical News Today

Results from a large-scale Phase III African trial of an experimental malaria vaccine by GlaxoSmithKline (GSK) shows that it continued to protect young children up to 18 months after vaccination. Malaria kills 660,000 people a year,...

PATH Malaria Vaccine Initiative To Collaborate With GlaxoSmithKline And Crucell In Development Of Second-generation Malaria Vaccine

Health : Medical News Today

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline (GSK). This collaboration is aimed at developing a second-gener...

Malaria Reduced By Approximately One-Third In African Infants: Results From Ongoing Phase III Clinical Trial

Health : Medical News Today

International African Vaccinology Conference, Cape Town, South Africa - Results from a pivotal, large-scale Phase III trial, published online in the New England Journal of Medicine, show that the RTS,S malaria vaccine candidate can ...

In Phase 3 children's study, malaria vaccine candidate reduces disease over 18 months of follow-up

Health : Medical News Today

Multilateral Initiative on Malaria Pan African Conference, Durban, South Africa - Results from a large-scale Phase III trial, presented today in Durban, show that the most clinically advanced malaria vaccine candidate, RTS,S, contin...

Comments


Copyright © 2016 Regator, LLC